These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7903542)

  • 21. Relationship between CD4 count and CD4% in HIV-infected people.
    Yu LM; Easterbrook PJ; Marshall T
    Int J Epidemiol; 1997 Dec; 26(6):1367-72. PubMed ID: 9447419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of survival in HIV-infected persons with 50 or fewer CD4 cells/mm3.
    Spino C; Kahn JO; Dolin R; Phair JP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(5):346-55. PubMed ID: 9342254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group.
    Cooper DA; Pehrson PO; Pedersen C; Moroni M; Oksenhendler E; Rozenbaum W; Clumeck N; Faber V; Stille W; Hirschel B
    AIDS; 1993 Feb; 7(2):197-207. PubMed ID: 8096703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic.
    Easterbrook PJ; Yu LM; Goetghebeur E; Boag F; McLean K; Gazzard B
    AIDS; 2000 Mar; 14(5):561-71. PubMed ID: 10780719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy.
    Yarchoan R; Venzon DJ; Pluda JM; Lietzau J; Wyvill KM; Tsiatis AA; Steinberg SM; Broder S
    Ann Intern Med; 1991 Aug; 115(3):184-9. PubMed ID: 1676252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents.
    Byers VS; Levin AS; Malvino A; Waites L; Robins RA; Baldwin RW
    AIDS Res Hum Retroviruses; 1994 Apr; 10(4):413-20. PubMed ID: 7915124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zalcitabine.
    Shelton MJ; O'Donnell AM; Morse GD
    Ann Pharmacother; 1993 Apr; 27(4):480-9. PubMed ID: 8097417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity.
    Stretcher BN; Pesce AJ; Frame PT; Greenberg KA; Stein DS
    AIDS; 1994 Jun; 8(6):763-9. PubMed ID: 8086134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. AIDS Clinical Trials Group Protocol 043 Study Group.
    McKinney RE; Wilfert C
    J Pediatr; 1994 Nov; 125(5 Pt 1):728-33. PubMed ID: 7965424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated serum calprotectin levels in HIV-infected patients: the calprotectin response during ZDV treatment is associated with clinical events.
    Müller F; Frøland SS; Aukrust P; Fagerhol MK
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):931-9. PubMed ID: 7914232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time.
    Graham NM; Piantadosi S; Park LP; Phair JP; Rinaldo CR; Fahey JL
    J Acquir Immune Defic Syndr (1988); 1993 Nov; 6(11):1258-66. PubMed ID: 7901384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD4 lymphocyte decline and survival in human immunodeficiency virus infection. The Military Medical Consortium for Applied Retroviral Research.
    Drabick JJ; Williams WJ; Tang DB; Sun W; Chung RC
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2039-47. PubMed ID: 1362886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group.
    BMJ; 1992 Jan; 304(6818):13-7. PubMed ID: 1346505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.
    Simberkoff MS; Hartigan PM; Hamilton JD; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM; Hawkes CA; Jensen PC; Kilmas NG; Labriola AM; O'Brien WA; Oster CN; Weinhold KJ; Wray NP; Pazner SB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):142-50. PubMed ID: 8556396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early predictors of survival in symptomatic HIV-infected persons treated with high-dose zidovudine.
    Bacchetti P; Moss AR; Andrews JC; Jacobson MA
    J Acquir Immune Defic Syndr (1988); 1992; 5(7):732-6. PubMed ID: 1535375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progression of HIV: follow-up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983-1985.
    Brettle RP; McNeil AJ; Burns S; Gore SM; Bird AG; Yap PL; MacCallum L; Leen CS; Richardson AM
    AIDS; 1996 Apr; 10(4):419-30. PubMed ID: 8728047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group.
    Merigan TC; Amato DA; Balsley J; Power M; Price WA; Benoit S; Perez-Michael A; Brownstein A; Kramer AS; Brettler D
    Blood; 1991 Aug; 78(4):900-6. PubMed ID: 1831059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of antiviral therapy on the natural history of human immunodeficiency virus infection in a cohort of hemophiliacs.
    Ragni MV; Kingsley LA; Zhou SJ
    J Acquir Immune Defic Syndr (1988); 1992; 5(2):120-6. PubMed ID: 1732503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
    Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of race/ethnicity on survival among HIV-infected patients in care.
    Lopez G; Simone B; Madariaga MG; Anderson J; Swindells S
    J Health Care Poor Underserved; 2009 Nov; 20(4):982-95. PubMed ID: 20168012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.